PE20190656A1 - Compuestos de tiazolo-piridina sustituida como inhibidores de malt1 - Google Patents

Compuestos de tiazolo-piridina sustituida como inhibidores de malt1

Info

Publication number
PE20190656A1
PE20190656A1 PE2019000282A PE2019000282A PE20190656A1 PE 20190656 A1 PE20190656 A1 PE 20190656A1 PE 2019000282 A PE2019000282 A PE 2019000282A PE 2019000282 A PE2019000282 A PE 2019000282A PE 20190656 A1 PE20190656 A1 PE 20190656A1
Authority
PE
Peru
Prior art keywords
malt1
inhibitors
pyridine compounds
tiazolo
compounds replaced
Prior art date
Application number
PE2019000282A
Other languages
English (en)
Inventor
Gagan Kukreja
Nageswara Rao Irlapati
Arun Rangnath Jagdale
Gokul Keruji Deshmukh
Vinod Popatrao Vyavahare
Kiran Chandrashekhar Kulkarni
Neelima Sinha
Venkata P Palle
Rajender Kumar Kamboj
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Ltd filed Critical Lupin Ltd
Publication of PE20190656A1 publication Critical patent/PE20190656A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Referido a compuestos de tiazolo-piridina sustituida, de formula (I), en el que R1 se selecciona de H, halogeno, ciano, entre otros; R2 se selecciona de alquilo, alquilo sustituido, cicloalquilo, entre otros; R3 se selecciona de heteroarilo, heteroarilo sustituido, arilo, entre otros. Un compuesto seleccionado es 1-(5-cloro-6-metoxipiridin-3-il)-3-(7-ciclopropil-2-metiltiazolo[5,4-b]piridin-6-il)urea. Ademas, se refiere a su uso como inhibidores de MALT1 en el tratamiento de enfermedades o trastornos inflamatorios y autoinmunes, como el cancer; metodos para sintetizar dichos compuestos y composiciones farmaceuticas que los contiene.
PE2019000282A 2016-07-29 2017-07-28 Compuestos de tiazolo-piridina sustituida como inhibidores de malt1 PE20190656A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN201621026107 2016-07-29

Publications (1)

Publication Number Publication Date
PE20190656A1 true PE20190656A1 (es) 2019-05-08

Family

ID=59745317

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2019000282A PE20190656A1 (es) 2016-07-29 2017-07-28 Compuestos de tiazolo-piridina sustituida como inhibidores de malt1

Country Status (15)

Country Link
US (1) US20190275012A9 (es)
JP (1) JP2019522035A (es)
KR (1) KR20190033607A (es)
CN (1) CN110312724A (es)
AU (1) AU2017302182B2 (es)
CA (1) CA3032334A1 (es)
CL (1) CL2019000221A1 (es)
DO (1) DOP2019000020A (es)
IL (1) IL289474A (es)
MX (1) MX2019001132A (es)
PE (1) PE20190656A1 (es)
PH (1) PH12019500214A1 (es)
RU (1) RU2019104890A (es)
SG (1) SG11201900745VA (es)
WO (1) WO2018020474A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI795381B (zh) 2016-12-21 2023-03-11 比利時商健生藥品公司 作為ｍａｌｔ１抑制劑之吡唑衍生物
WO2018165385A1 (en) 2017-03-08 2018-09-13 Cornell University Inhibitors of malt1 and uses thereof
JP7271540B2 (ja) * 2017-11-17 2023-05-11 へパジーン セラピューティクス （エイチケイ） リミテッド Ａｓｋ１阻害剤としての尿素誘導体
SG11202006200RA (en) 2017-12-28 2020-07-29 Massachusetts Gen Hospital Targeting the cbm signalosome complex induces regulatory t cells to inflame the tumor microenvironment
KR20210024002A (ko) * 2018-06-18 2021-03-04 얀센 파마슈티카 엔.브이. Malt1 억제제로서의 피라졸 유도체
EA202190055A1 (ru) * 2018-06-18 2021-04-23 Янссен Фармацевтика Нв Производные пиразола в качестве ингибиторов malt1
CN109265453A (zh) * 2018-10-23 2019-01-25 华侨大学 一种用作caspase-3激活剂的缩氨基脲类衍生物及其应用
IL303962A (en) * 2018-11-28 2023-08-01 Takeda Pharmaceuticals Co The tricyclic compound
BR112021019799A2 (pt) 2019-04-11 2021-12-07 Janssen Pharmaceutica Nv Derivados contendo anéis de piridina como inibidores de malt1
WO2021000855A1 (en) * 2019-07-01 2021-01-07 Qilu Regor Therapeutics Inc. Malt1 inhibitors and uses thereof
WO2021063735A1 (en) * 2019-10-02 2021-04-08 Basf Se New bicyclic pyridine derivatives
WO2021134004A1 (en) * 2019-12-27 2021-07-01 Schrodinger, Inc. Cyclic compounds and methods of using same
US20230192685A1 (en) * 2020-05-27 2023-06-22 Takeda Pharmaceutical Company Limited Method for producing heterocyclic compound
US20230235077A1 (en) 2020-06-24 2023-07-27 The General Hospital Corporation Materials and methods of treating cancer
CN116710089A (zh) * 2020-11-12 2023-09-05 莫诺泰罗斯疗法公司 治疗癌症的材料和方法
KR20240130085A (ko) 2021-12-30 2024-08-28 상하이 한서 바이오메디컬 컴퍼니 리미티드 트리시클릭 유도체 억제제, 이의 제조 방법 및 응용
CN116535424A (zh) * 2022-01-26 2023-08-04 武汉誉祥医药科技有限公司 作为malt1抑制剂的三并环化合物及其药物组合物和应用
KR20240144146A (ko) 2022-02-02 2024-10-02 오노 야꾸힝 고교 가부시키가이샤 Malt1 저해약을 유효 성분으로서 포함하는 암 치료제
WO2023148501A1 (en) 2022-02-03 2023-08-10 C4X Discovery Limited Heterocyclic derivatives as malt1 inhibitors
TW202345806A (zh) 2022-03-31 2023-12-01 美商艾伯維有限公司 噻唑并〔５，４－ｂ〕吡啶ｍａｌｔ－１抑制劑
WO2023192506A1 (en) * 2022-03-31 2023-10-05 Rarified Biosciences, Inc. Malt1 modulators and uses thereof
WO2024116528A1 (ja) * 2022-11-28 2024-06-06 ユニマテック株式会社 含フッ素ピリドン化合物およびその製造方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
TR200201204T2 (tr) * 1999-11-05 2002-08-21 Warner Lambert Company ACAT inhibitörleriyle plak rüptürünün engellenmesi.
AU2003222667A1 (en) * 2002-04-23 2003-11-10 Chugai Seiyaku Kabushiki Kaisha 1,3-thiazoles as lxr modulators in the treatment of cardiovascular diseases
WO2008146259A2 (en) 2007-06-01 2008-12-04 University Of Lausanne Malt1 specific cleavage in assay and screening method
EP2222326B2 (en) 2007-11-21 2015-02-25 Vib Vzw Inhibitors of malt1 proteolytic activity and uses thereof
CA2842976A1 (en) * 2011-07-26 2013-01-31 Grunenthal Gmbh Substituted bicyclic aromatic carboxamide and urea derivatives as vanilloid receptor ligands
JP6069321B2 (ja) * 2011-08-02 2017-02-01 ヘルムホルツ ツェントラム ミュンヘン ドイチェス フォーシュングスツェントラム フュール ゲズントハイト ウント ウンヴェルト ゲーエムベーハーＨｅｌｍｈｏｌｔｚ Ｚｅｎｔｒｕｍ Ｍｕｅｎｃｈｅｎ Ｄｅｕｔｓｃｈｅｓ Ｆｏｒｓｃｈｕｎｇｓｚｅｎｔｒｕｍ Ｆｕｅｒ Ｇｅｓｕｎｄｈｅｉｔ Ｕｎｄ Ｕｍｗｅｌｔ Ｇｍｂｈ フェノチアジン誘導体によるｍａｌｔ１プロテアーゼの選択的阻害
WO2013053765A1 (en) 2011-10-11 2013-04-18 Proyecto De Biomedicina Cima, S.L. A non-human animal model of mucosa-associated lymphoid tissue (malt) lymphoma
US9592223B2 (en) 2012-11-09 2017-03-14 Cornell University Small molecule inhibitors of MALT1
WO2014086478A1 (en) * 2012-12-03 2014-06-12 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Inhibitors of malt1 protease
EP4001275A1 (en) 2013-06-26 2022-05-25 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH (s)-enantiomer of mepazine as paracaspase (malt1) inhibitor for the treatment of cancer
WO2015110406A1 (en) 2014-01-21 2015-07-30 Helmholtz Zentrum München Means and methods for detecting activated malt1
MX2016015544A (es) * 2014-05-28 2017-03-23 Novartis Ag Nuevos derivados de pirazolo pirimidina y su uso como inhibidores de malt1.
DE102015210224A1 (de) 2015-06-02 2016-12-08 Universitätsklinikum Hamburg-Eppendorf Neuer wirkstoff zur behandlung von krebs
EP3341007B1 (en) 2015-08-28 2020-12-23 Cornell University Malt1 inhibitors and uses thereof
JPWO2017057695A1 (ja) 2015-09-30 2018-07-19 東レ株式会社 ジフェニルピラゾール誘導体及びその医薬用途
WO2017081641A1 (en) 2015-11-13 2017-05-18 Novartis Ag Novel pyrazolo pyrimidine derivatives
WO2018165385A1 (en) * 2017-03-08 2018-09-13 Cornell University Inhibitors of malt1 and uses thereof

Also Published As

Publication number Publication date
CN110312724A (zh) 2019-10-08
US20190275012A9 (en) 2019-09-12
IL289474A (en) 2022-02-01
RU2019104890A3 (es) 2020-08-31
AU2017302182A1 (en) 2019-03-07
CL2019000221A1 (es) 2019-06-07
US20190160045A1 (en) 2019-05-30
WO2018020474A1 (en) 2018-02-01
RU2019104890A (ru) 2020-08-31
AU2017302182B2 (en) 2021-11-04
JP2019522035A (ja) 2019-08-08
KR20190033607A (ko) 2019-03-29
DOP2019000020A (es) 2019-04-30
PH12019500214A1 (en) 2019-10-28
MX2019001132A (es) 2019-12-16
CA3032334A1 (en) 2018-02-01
SG11201900745VA (en) 2019-02-27

Similar Documents

Publication Publication Date Title
PE20190656A1 (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1
PE20190395A1 (es) Pirimidin-2-ilamino-1h-pirazoles como inhibidores de lrrk2 para el uso en el tratamiento de trastornos neurodegenerativos
AR119651A1 (es) Compuestos heterocíclicos y de heteroarilo para tratar la enfermedad de huntington
UY38076A (es) Derivados de tetrahidroquinazolina útiles como agentes anticáncer
CL2018003701A1 (es) Compuestos heterocíclicos como inmunomoduladores.
UY38070A (es) Derivados de quinazolina y piridopirimidina sustituidos útiles como agentes anticáncer
PE20191613A1 (es) Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret
SV2018005794A (es) Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos
CO2018004124A2 (es) Compuestos heterocíclicos
NI201700095A (es) Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos
CL2016002148A1 (es) Derivados de fenilen-1,5-diamina 2,4-disustituidos y aplicaciones de los mismos, y composiciones farmacéuticas y composiciones farmacéuticamente aceptables preparadas a partir de los mismos.
EA201691302A1 (ru) Новые гетероциклические соединения
CO2018011408A2 (es) Compuestos de pirimidina como inhibidores de la quinasa jak
CU20160149A7 (es) Compuestos de heteroarilo o arilo bicíclicos fusionados y su uso como inhibidores de irak4
PE20190811A1 (es) Derivados de pirazolopirimidinas como inhibidor de quinasa
EA201691625A1 (ru) Ароматические гетероциклические соединения как противовоспалительные соединения
EA201592199A1 (ru) Производные бипиразола в качестве ингибиторов jak
UY35898A (es) ?compuestos inhibidores de syk y composiciones que los comprenden?.
AR100886A1 (es) 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas
ECSP17021897A (es) Compuestos y composiciones como inhibidores de quinasa raf
CL2015002635A1 (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
PE20170946A1 (es) 2-amino-6-(difluorometil)- 5,5-difluoro-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1
AR102981A1 (es) Inhibidores de la necrosis celular y métodos de preparación de los mismos
PE20211246A1 (es) Compuestos biciclicos para su uso como inhibidores de rip1 quinasa
CU20180028A7 (es) DERIVADOS DE IMIDAZO[4,5-b]PIRIDINA, ÚTILES COMO INHIBIDORES DUALES DE DYRK1/CLK1 Y COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN